Omeros Announces Successful Primate Study in OncotoX-AML Drug Program
Business Wire (Tue, 17-Feb 8:45 AM ET)
Omeros Announces First Commercial Sales of YARTEMLEA
Business Wire (Tue, 27-Jan 9:00 AM ET)
Omeros Reschedules YARTEMLEA FDA Approval Call—Landmark Therapy Preps for January 2026 U.S. Launch
Market Chameleon (Mon, 29-Dec 2:06 AM ET)
Omeros Announces New Date for YARTEMLEA Approval Conference Call
Business Wire (Fri, 26-Dec 6:36 PM ET)
OMER Call Spread Buyers Net 26.4% in a Day as FDA Approval Sparks Bullish Surge
Market Chameleon (Wed, 24-Dec 6:35 AM ET)
FDA Approval of Omeros’ YARTEMLEA Establishes New Standard of Care for TA-TMA
Market Chameleon (Wed, 24-Dec 4:16 AM ET)
FDA Approves Omeros' YARTEMLEA - First and Only Therapy Indicated for TA-TMA
Business Wire (Wed, 24-Dec 9:00 AM ET)
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Omeros trades on the NASDAQ stock market under the symbol OMER.
As of March 5, 2026, OMER stock price declined to $11.39 with 514,030 million shares trading.
OMER has a beta of 0.51, meaning it tends to be less sensitive to market movements. OMER has a correlation of 0.00 to the broad based SPY ETF.
OMER has a market cap of $807.56 million. This is considered a Small Cap stock.
Last quarter Omeros reported $0 in Revenue and -$.34 earnings per share. This fell short of revenue expectation by $-312,500 and exceeded earnings estimates by $.18.
In the last 3 years, OMER traded as high as $17.65 and as low as $.92.
The top ETF exchange traded funds that OMER belongs to (by Net Assets): VTI, IWM, VXF, IWO, SCHA.
OMER has outperformed the market in the last year with a return of +42.7%, while the SPY ETF gained +18.4%. In the last 3 month period, OMER beat the market returning +3.3%, while SPY returned -1.0%. However, in the most recent 2 weeks OMER has underperformed the stock market by returning -3.1%, while SPY returned -1.5%.
OMER support price is $11.21 and resistance is $11.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OMER shares will trade within this expected range on the day.
